Cytochrome P450 Enzymes and Drug Metabolism in Humans

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · see citing works

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature

Nelson, D. R., Koymans, L. M. H., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,946 · see citing works

Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival

Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0637 · Cited by 2,356 · see citing works

Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture.

Conney, A. H. (1982) · PubMed · Cited by 1,557 · see citing works

Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects

Ingelman‐Sundberg, M., Sim, S. C., Gomez, A. V., & Rodríguez‐Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,165 · see citing works

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

Ingelman‐Sundberg, M. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,111 · see citing works

Predicting in vivo drug interactions from in vitro drug discovery data

Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 911 · see citing works

Cytochrome P450 Structure, Function and Clinical Significance: A Review

Palrasu, M., & Nagini, S. (2017) · Current Drug Targets · doi:10.2174/1389450118666170125144557 · Cited by 855 · see citing works

Inhibition and Induction of Cytochrome P450 and the Clinical Implications

Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 827 · see citing works

The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans

Danielson, B. S. P. P. B. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 775 · see citing works

Pharmacogenomics and Individualized Drug Therapy

Eichelbaum, M. F., Ingelman‐Sundberg, M., & Evans, W. E. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 719 · see citing works

Drug Metabolism in the Liver

Almazroo, O. A., Miah, M. K., & Venkataramanan, R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.001 · Cited by 691 · see citing works

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

Ingelman‐Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 678 · see citing works

PHASE II DRUG METABOLIZING ENZYMES

Jancova, P., Anzenbacher, P., & Anzenbacherová, E. (2010) · Biomedical Papers · doi:10.5507/bp.2010.017 · Cited by 611 · see citing works

Inhibition and induction of human cytochrome P450 enzymes: current status

Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 571 · see citing works

Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

Caudle, K. E., Sangkuhl, K., Whirl‐Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., Gammal, R. S., Relling, M. V., Scott, S. A., Hertz, D. L., et al. (2019) · Clinical and Translational Science · doi:10.1111/cts.12692 · Cited by 545 · see citing works

Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

Zhou, S., Chan, S. Y., Goh, B. C., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 512 · see citing works

Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals

Rendić, S., & Guengerich, F. P. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500444e · Cited by 479 · see citing works

Induction of Drug Metabolism: The Role of Nuclear Receptors

Handschin, C., & Meyer, U. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.2 · Cited by 467 · see citing works

Inhibition and induction of CYP enzymes in humans: an update

Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 422 · see citing works

MicroRNA Regulates the Expression of Human Cytochrome P450 1B1

Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T., & Yokoi, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1403 · Cited by 406 · see citing works

Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps.

Lang, N. P., Butler, M. A., Massengill, J., Lawson, M., Stotts, R. C., Hauer‐Jensen, M., & Kadlubar, F. F. (1994) · PubMed · Cited by 391 · see citing works

Recent Structural Insights into Cytochrome P450 Function

Guengerich, F. P., Waterman, M. R., & Egli, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.006 · Cited by 387 · see citing works

The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes

Parkinson, A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.010 · Cited by 385 · see citing works

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

Ingelman‐Sundberg, M. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0819-z · Cited by 355 · see citing works

Applications of CYP450 Testing in the Clinical Setting

Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 355 · see citing works

A potentially hazardous interaction between erythromycin and midazolam

Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J., & Neuvonen, P. J. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.25 · Cited by 351 · see citing works

Impact of CYP2D6 genotype on postoperative tramadol analgesia

Stamer, U. M., Lehnen, K., Höthker, F., Bayerer, B., Wolf, S., Hoeft, A., & Stüber, F. (2003) · Pain · doi:10.1016/s0304-3959(03)00212-4 · Cited by 329 · see citing works

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

Lima, J. J., Thomas, C. D., Barbarino, J. M., Desta, Z., Driest, S. L. V., Rouby, N. M. E., Johnson, J. A., Cavallari, L. H., Shakhnovich, V., Thacker, D. L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2015 · Cited by 320 · see citing works

Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes

Lin, J. H., & Lu, A. Y. H. (2001) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.535 · Cited by 286 · see citing works

Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator

Elcombe, C. R., Peffer, R. C., Wolf, D. C., Bailey, J. P., Bars, R., Bell, D., Cattley, R. C., Ferguson, S., Geter, D. R., Goetz, A. K., et al. (2013) · Critical Reviews in Toxicology · doi:10.3109/10408444.2013.835786 · Cited by 264 · see citing works

Reactions and enzymes in the metabolism of drugs and other xenobiotics

Testa, B., Pedretti, A., & Vistoli, G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.017 · Cited by 254 · see citing works

Mechanisms of cytochrome P450 induction

Tompkins, L. M., & Wallace, A. D. (2007) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20180 · Cited by 250 · see citing works

Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs.

Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng, Y., Guengerich, F. P., & Inui, Y. (1996) · PubMed · Cited by 244 · see citing works

Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer

Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., Ogishima, T., Okino, S. T., Li, L., Tanaka, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2545 · Cited by 202 · see citing works

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain

Miksys, S. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00136-9 · Cited by 198 · see citing works

Phenobarbital Indirectly Activates the Constitutive Active Androstane Receptor (CAR) by Inhibition of Epidermal Growth Factor Receptor Signaling

Mutoh, S., Sobhany, M., Moore, R., Perera, L., Pedersen, L. G., Sueyoshi, T., & Negishi, M. (2013) · Science Signaling · doi:10.1126/scisignal.2003705 · Cited by 197 · see citing works

Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor

Kawajiri, K., & Fujii-Kuriyama, Y. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.038 · Cited by 197 · see citing works

Cytochrome P450 CYP1B1 protein expression:

McFadyen, M. C. E., McLeod, H. L., Jackson, F. C., Melvin, W. T., Doehmer, J., & Murray, G. I. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00643-8 · Cited by 187 · see citing works

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update

Karnes, J. H., Rettie, A. E., Somogyi, A. A., Huddart, R., Fohner, A. E., Formea, C. M., Lee, M. T. M., LLerena, A., Whirl‐Carrillo, M., Klein, T. E., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2008 · Cited by 184 · see citing works

Drug–drug–gene interactions and adverse drug reactions

Malki, M. A., & Pearson, E. R. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0122-0 · Cited by 169 · see citing works

Simultaneous Absolute Quantification of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection

Kawakami, H., Ohtsuki, S., Kamiie, J., Suzuki, T., Abe, T., & Terasaki, T. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22255 · Cited by 165 · see citing works

Understanding and preventing drug–drug and drug–gene interactions

Tannenbaum, C., & Sheehan, N. L. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.910111 · Cited by 165 · see citing works

Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods

Coelho, M. M., Fernandes, C., Remião, F., & Tiritan, M. E. (2021) · Molecules · doi:10.3390/molecules26113113 · Cited by 161 · see citing works

Structural insights from a P450 Carrier Protein complex reveal how specificity is achieved in the P450 BioI ACP complex

Cryle, M. J., & Schlichting, I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805983105 · Cited by 153 · see citing works

Mechanistic aspects of CYP74 allene oxide synthases and related cytochrome P450 enzymes

BRASH, A. R. (2009) · Phytochemistry · doi:10.1016/j.phytochem.2009.08.005 · Cited by 135 · see citing works

Cytochrome P450–mediated drug metabolism in the brain

Miksys, S. L., & Tyndale, R. F. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120133 · Cited by 132 · see citing works

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine

Brown, S.-A. N., & Pereira, N. L. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8010008 · Cited by 123 · see citing works

Designing better drugs: predicting cytochrome P450 metabolism

de Groot, M. J. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.001 · Cited by 122 · see citing works

Involvement of cytochrome P450 enzymes in inflammation and cancer: a review

Stipp, M. C., & Acco, A. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04181-2 · Cited by 121 · see citing works

CYP450 pharmacogenetics for personalizing cancer therapy

van Schaik, R. H. N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.002 · Cited by 119 · see citing works

Modes of heme binding and substrate access for cytochrome P450 CYP74A revealed by crystal structures of allene oxide synthase

Li, L., Chang, Z., Pan, Z., Fu, Z., & Wang, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804099105 · Cited by 113 · see citing works

Pharmaceutical Excipients and Drug Metabolism: A Mini-Review

Patel, R., Barker, J., & ElShaer, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218224 · Cited by 110 · see citing works

Post-translational and Post-transcriptional Modifications of Pregnane X Receptor (PXR) in Regulation of the Cytochrome P450 Superfamily

Smutný, T., Mani, S., & Pávek, P. (2013) · Current Drug Metabolism · doi:10.2174/1389200214666131211153307 · Cited by 106 · see citing works

Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review

Chen, M., Zhou, S., Fabriaga, E., Zhang, P.-H., & Zhou, Q. (2018) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2018.01.009 · Cited by 101 · see citing works

How Common are Drug and Gene Interactions? Prevalence in a Sample of 1143 Patients with CYP2C9 , CYP2C19 and CYP2D6 Genotyping

Verbeurgt, P., Mamiya, T., & Oesterheld, J. R. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.6 · Cited by 99 · see citing works

miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression

Mu, W., Hu, C., Zhang, H., Qu, Z., Cen, J., Qiu, Z., Li, C., Ren, H., Li, Y., He, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.23 · Cited by 95 · see citing works

The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients

Mann, A., Miksys, S. L., Gaedigk, A., Kish, S. J., Mash, D. C., & Tyndale, R. F. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.014 · Cited by 92 · see citing works

Quantitative Prediction of Human Pregnane X Receptor and Cytochrome P450 3A4 Mediated Drug-Drug Interaction in a Novel Multiple Humanized Mouse Line

Hasegawa, M., Kapelyukh, Y., Tahara, H., Seibler, J., Rode, A., Krueger, S., Lee, D. N., Wolf, C. R., & Scheer, N. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071845 · Cited by 89 · see citing works

Complicated Pain Management in a CYP450 2D6 Poor Metabolizer

Foster, A. E., Mobley, E., & Wang, Z. (2007) · Pain Practice · doi:10.1111/j.1533-2500.2007.00153.x · Cited by 85 · see citing works

Crystal Structures of Epothilone D-bound, Epothilone B-bound, and Substrate-free Forms of Cytochrome P450epoK

Nagano, S., Li, H., Shimizu, H., Nishida, C. R., Ogura, H., de Montellano, P. R. O., & Poulos, T. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308115200 · Cited by 82 · see citing works

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Tang, X., & Chen, S. (2015) · Current Drug Metabolism · doi:10.2174/138920021602150713114159 · Cited by 82 · see citing works

Novel advances in cytochrome P450 research

Singh, D., Kashyap, A., Pandey, R. V., & Saini, K. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.003 · Cited by 81 · see citing works

Differences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary Hepatocytes

Park, H., Choi, Y.-J., Kim, J. W., Chun, H., Im, I., Yoon, S., Han, Y., Song, C.-W., & Kim, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132992 · Cited by 81 · see citing works

Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy

Sadée, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer, R. A., & Johnson, A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.314 · Cited by 78 · see citing works

CYP-mediated drug metabolism in the brain impacts drug response

McMillan, D. M., & Tyndale, R. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.008 · Cited by 77 · see citing works

Inhibitors of cytochrome P450 (CYP) 1B1

Dutour, R., & Poirier, D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.042 · Cited by 73 · see citing works

Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects

Rendić, S. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03025-z · Cited by 73 · see citing works

The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies

Zarezadeh, M., Saedisomeolia, A., Shekarabi, M., Khorshidi, M., Emami, M. R., & Müller, D. J. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02421-y · Cited by 71 · see citing works

An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview

Zahoor, I., Rui, B., Khan, J. A., Datta, I., & Giri, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03733-2 · Cited by 69 · see citing works

Cytochrome P450 enzyme isoforms and their therapeutic implications: An update

Kalra, B. S. (2007) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.30351 · Cited by 65 · see citing works

Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it

Verma, H., Bahia, M. S., Choudhary, S., Singh, P. K., & Silakari, O. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1632886 · Cited by 63 · see citing works

Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma

Raunio, H., Juvonen, R. O., Pasanen, M., Pelkonen, O., Pääkkö, P. K., & Soini, Y. (1998) · Hepatology · doi:10.1002/hep.510270217 · Cited by 61 · see citing works

Cytochrome P450 Metabolism of Polyunsaturated Fatty Acids and Neurodegeneration

Sarparast, M., Dattmore, D. A., Alan, J. K., & Lee, K. S. S. (2020) · Nutrients · doi:10.3390/nu12113523 · Cited by 59 · see citing works

The chemical nature and reactivity of cytochrome P-450

Hill, H. A. O., Röder, A., & Williams, R. J. (1970) · Structure and bonding · doi:10.1007/3-540-05257-7_3 · Cited by 59 · see citing works

The Past, Present and Future of Pharmacoepigenomics

Ingelman‐Sundberg, M., & Gomez, A. V. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.59 · Cited by 58 · see citing works

The Effect of CYP2D6 Polymorphisms on the Response to Pain Treatment for Pediatric Sickle Cell Pain Crisis

Brousseau, D. C., McCarver, D. G., Drendel, A. L., Divakaran, K., & Panepinto, J. A. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.01.049 · Cited by 57 · see citing works

Expression of cytochrome P450 isozyme transcripts and activities in human livers

Liu, J., Lu, Y., Corton, J. C., & Klaassen, C. D. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1867929 · Cited by 57 · see citing works

Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy

Karkhanis, A. V., Hong, Y., & Chan, E. C. Y. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.017 · Cited by 56 · see citing works

Modulation of Cytochrome-P450 Inhibition (CYP) in Drug Discovery: A Medicinal Chemistry Perspective

Kumar, S., Sharma, R. K., & Roychowdhury, A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801323180 · Cited by 54 · see citing works

CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma

Mitsui, Y., Chang, I., Fukuhara, S., Hiraki, M., Arichi, N., Yasumoto, H., Hirata, H., Yamamura, S., Shahryari, V., Deng, G., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1951-0 · Cited by 53 · see citing works

Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases

Navarro‐Mabarak, C., Camacho‐Carranza, R., & Espinosa-Aguirre, J. J. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1439502 · Cited by 53 · see citing works

Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity

Tao, G., Huang, J., Moorthy, B., Wang, C., Hu, M. C., Gao, S., & Ghose, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1815705 · Cited by 51 · see citing works

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole

Türk, D., Hanke, N., Wolf, S., Frechen, S., Eißing, T., Wendl, T., Schwab, M. G., & Lehr, T. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00777-x · Cited by 48 · see citing works

Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies

Sneha, S., Baker, S. C., Green, A. R., Storr, S. J., Aiyappa‐Maudsley, R., Martin, S. G., & Pors, K. (2021) · Biomedicines · doi:10.3390/biomedicines9030290 · Cited by 48 · see citing works

Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives

Storelli, F., Samer, C. F., Reny, J., Desmeules, J. A., & Daali, Y. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0650-9 · Cited by 47 · see citing works

Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification

Wang, Y., He, X., Li, C., Ma, Y., Xue, W.-C., Hu, B., Wang, J., Zhang, T., & Zhang, F. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112235 · Cited by 45 · see citing works

Predicting drug pharmacokinetics in humans from in vitro metabolism studies

McGinnity, D. F., & Riley, R. J. (2001) · Biochemical Society Transactions · doi:10.1042/0300-5127:0290135 · Cited by 44 · see citing works

Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them

Guo, Z., Johnson, V., Barrera, J., Porras, M., Ugarte, D. H., Hernández, I., McGarrah, P. W., & Potter, D. A. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9749-6 · Cited by 43 · see citing works

Pharmacogenetics of antipsychotics: Clinical utility and implementation

Arranz, M. J., Salazar, J., & Hernández, M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113058 · Cited by 43 · see citing works

Predicting drug pharmacokinetics in humans from in vitro metabolism studies

McGinnity, D. F., & Riley, R. J. (2001) · Biochemical Society Transactions · doi:10.1042/bst0290135 · Cited by 41 · see citing works

Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy

Karlgren, M., & Ingelman‐Sundberg, M. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.1.61 · Cited by 38 · see citing works

Cytochrome P450 enzyme-mediated auto-enhanced photodynamic cancer therapy of co-nanoassembly between clopidogrel and photosensitizer

Wang, Q., Sun, M., Li, D., Li, C., Luo, C., Wang, Z., Zhang, W., Yang, Z., Yao, F., Wang, S., et al. (2020) · Theranostics · doi:10.7150/thno.42633 · Cited by 38 · see citing works

Cytochrome P450 humanised mice

Gonzalez, F. J. (2004) · Human Genomics · doi:10.1186/1479-7364-1-4-300 · Cited by 36 · see citing works

CNVs of human genes and their implication in pharmacogenetics

Johansson, I., & Ingelman‐Sundberg, M. (2008) · Cytogenetic and Genome Research · doi:10.1159/000184709 · Cited by 35 · see citing works

Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease

Morgan, E. T., Skubic, C., Lee, C., Cokan, K. B., & Rozman, D. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1817061 · Cited by 33 · see citing works

Post‐translational dual regulation of cytochrome P450 aromatase at the catalytic and protein levels by phosphorylation/dephosphorylation

Hayashi, T., & Harada, N. (2014) · FEBS Journal · doi:10.1111/febs.13021 · Cited by 31 · see citing works

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer

Puszkiel, A., Arellano, C., Vachoux, C., Evrard, A., Morvan, V. L., Boyer, J.-C., Robert, J., Delmas, C., Dalenc, F., Debled, M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2077 · Cited by 31 · see citing works

Enzyme Inhibition

Palmer, T., & Bonner, P. L. R. (2011) · Elsevier eBooks · doi:10.1533/9780857099921.2.126 · Cited by 31 · see citing works

Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature

Barros-Oliveira, M. D. C., Costa-Silva, D. R., dos Santos, A. R., Pereira, R. D. O., Soares, J. M., & da Silva, B. B. (2021) · Clinics · doi:10.6061/clinics/2021/e2846 · Cited by 30 · see citing works

X-ray structure of nitric oxide reductase (cytochrome P450nor) at atomic resolution

Shimizu, H., Park, S., Shiro, Y., & Adachi, S. (2001) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444901017383 · Cited by 28 · see citing works

Enzymes and Energetics

Pelley, J. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07446-9.00004-0 · Cited by 26 · see citing works

Understanding electron transport systems of Streptomyces cytochrome P450

Chun, Y., Shimada, T., Waterman, M. R., & Guengerich, F. P. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341183 · Cited by 25 · see citing works

A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients

Idrissi, H. H., Hmimech, W., Khorb, N. E., Akoudad, H., Habbal, R., & Nadifi, S. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3132-0 · Cited by 25 · see citing works

The Role of Pharmacogenetics in Smoking

El‐Boraie, A., & Tyndale, R. F. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2345 · Cited by 25 · see citing works

Effect of High‐Dose Vitamin C on Hepatic Cytochrome P450 3A4 Activity

van Heeswijk, R. P. G., Cooper, C., Foster, B. C., Chauhan, B. M., Shirazi, F. H., Seguin, I., Phillips, E. J., & Mills, E. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.12.1725 · Cited by 16 · see citing works

Drug Related Genetic Polymorphisms Affecting Adverse Reactions to Methotrexate, Vinblastine, Doxorubicin and Cisplatin in Patients With Urothelial Cancer

Tsuchiya, N., Inoue, T., Narita, S., Kumazawa, T., Saito, M., Obara, T., Tsuruta, H., Horikawa, Y., Yuasa, T., Satoh, S., et al. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.08.035 · Cited by 16 · see citing works

Regulation of drug-metabolizing enzymes by local and systemic liver injuries

Guo, Y., Hu, B., Xie, Y., Billiar, T. R., Sperry, J. L., Huang, M., & Xie, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1139574 · Cited by 16 · see citing works

Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism

Banerjee, B. D., Kumar, R., Thamineni, K. L., Shah, H. K., Thakur, G., & Sharma, T. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200110153304 · Cited by 16 · see citing works

Digital Microfluidics-Enabled Analysis of Individual Variation in Liver Cytochrome P450 Activity

Sathyanarayanan, G., Haapala, M., & Sikanen, T. M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03258 · Cited by 15 · see citing works

Deregulation of signaling pathways controlling cell survival and proliferation in cancer cells alters induction of cytochrome P450 family 1 enzymes

Krkoška, M., Svobodová, J., Kabátková, M., Zapletal, O., Vaculová, A. H., Nekvindová, J., & Vondráček, J. (2021) · Toxicology · doi:10.1016/j.tox.2021.152897 · Cited by 12 · see citing works

CYP2A6 overexpression in human lung cancers correlates with a high malignant status

Matsuda, Y., Yamakawa, K., Saoo, K., Hosokawa, K., Yokohira, M., Kuno, T., Iwai, J., Shirai, T., Obika, K., Kamataki, T., et al. (2007) · Oncology Reports · doi:10.3892/or.18.1.53 · Cited by 11 · see citing works

Prediction of Cytochrome 450 Mediated Drug-Drug Interactions by Three-Dimensional Cultured Hepatocytes

Shen, C., & Meng, Q. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712802762293 · Cited by 11 · see citing works

Genetic Polymorphism of CYP2C19 in Pakistani Population.

Riaz, S., Din, S. M., Tareen, U., Tariq, F. A., Latif, Y., Siddiqi, S., Sultan, A., & Mansoor, A. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100644 · Cited by 11 · see citing works

Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem

Trieu, L., & Murray, M. T. (2000) · Xenobiotica · doi:10.1080/004982500237730 · Cited by 8 · see citing works

Cytochrome P450 content in primary tumors and liver metastases of patients with metastatic colorectal cancer

Бурлака, А. П., Вірко, С. В., Burlaka, A. A., Chernobaĭ, V. A., Yatsyna, O. I., & Ganusevich, І. І. (2020) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-42-no-4.15310 · Cited by 7 · see citing works

Activities of Rat Cytochrome P450 3A and 2C Isoforms are Increased In Vivo by Magnesium Sulfate as Evidenced by Enhanced Oxidation of Bupivacaine and Testosterone in Liver Microsomes

Saito, M., Okutomi, T., Shimizu, M., Matsumoto, Y., Yamazaki, H., & Hoka, S. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.201 · Cited by 6 · see citing works

PharmacodynamicsHow drugs elicit a physiological effect

Aldred, E. M. (2009) · Elsevier eBooks · doi:10.1016/b978-0-443-06898-0.00019-0 · Cited by 4 · see citing works

A new opportunity for nanomedicines: Micellar cytochrome P450 inhibitors to improve drug efficacy in a cancer therapy model

Paolini, M. S., Poul, L., Darmon, A., Germain, M., Pottier, A., Lévy, L., & Vibert, É. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.03.006 · Cited by 3 · see citing works

Pharmacogenomics: Driving Personalized Medicine

Sadée, W., Wang, D., Hartmann, K., & Toland, A. E. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000810 · Cited by 249 · see citing works

Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review

Abdelmonem, B. H., Abdelaal, N. M., Anwer, E. K. E., Rashwan, A. A., Hussein, M. A., Ahmed, Y. F., Khashana, R., Hanna, M. M., & Abdelnaser, A. (2024) · Biomedicines · doi:10.3390/biomedicines12071467 · Cited by 175 · see citing works

Drug induced liver injury – a 2023 update

Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2023.2261848 · Cited by 150 · see citing works

CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms

Zhang, Y., Wang, Z., Wang, Y., Jin, W., Zhang, Z., Jin, L., Qian, J., & Zheng, L. (2024) · PeerJ · doi:10.7717/peerj.18636 · Cited by 127 · see citing works

Synergy, Additive Effects, and Antagonism of Drugs with Plant Bioactive Compounds

Chaachouay, N. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4010004 · Cited by 123 · see citing works

Eicosanoids in inflammation in the blood and the vessel

Yamaguchi, A. A., Botta, E., & Holinstat, M. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.997403 · Cited by 114 · see citing works

Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease

Schwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112 · see citing works

Exploring the Interplay of Antioxidants, Inflammation, and Oxidative Stress: Mechanisms, Therapeutic Potential, and Clinical Implications

Altanam, S. Y., Darwish, N., & Bakillah, A. (2025) · Diseases · doi:10.3390/diseases13090309 · Cited by 92 · see citing works

Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective

Rani, J., Dhull, S. B., Rose, P. K., & Kidwai, M. K. (2024) · Phytomedicine · doi:10.1016/j.phymed.2023.155142 · Cited by 91 · see citing works

Divergent amplifications of CYP9A cytochrome P450 genes provide two noctuid pests with differential protection against xenobiotics

Shi, Y., Liu, Q., Lu, W., Yuan, J., Yang, Y., Oakeshott, J. G., & Wu, Y. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308685120 · Cited by 85 · see citing works

Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review

Angelopoulou, E., Paudel, Y. N., Papageorgiou, S. G., & Piperi, C. (2022) · Brain Sciences · doi:10.3390/brainsci12020175 · Cited by 73 · see citing works

Drug metabolism and drug transport of the 100 most prescribed oral drugs

Iversen, D. B., Andersen, N. E., Dunvald, A. D., Pottegård, A., & Stage, T. B. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13780 · Cited by 72 · see citing works

Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review

Mokhosoev, I. M., Astakhov, D. V., Terentiev, A. A., & Moldogazieva, N. T. (2024) · Cells · doi:10.3390/cells13231958 · Cited by 78 · see citing works

Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics

Uti, D. E., Alum, E. U., Atangwho, I. J., Ugwu, O. P.-C., Egbung, G. E., & Aja, P. M. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03412-z · Cited by 70 · see citing works

Drug–drug interactions involving classic psychedelics: A systematic review

Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 74 · see citing works

A review of the current trends in computational approaches in drug design and metabolism

Ouma, R. B. O., Ngari, S. M., & Kibet, J. K. (2024) · Discover Public Health · doi:10.1186/s12982-024-00229-3 · Cited by 69 · see citing works

An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations

McCurdy, C. R., Sharma, A., Smith, K. E., Veltri, C. A., Weiss, S. T., White, C. M., & Grundmann, O. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2305798 · Cited by 61 · see citing works

In vitro metabolism of the emerging contaminant 6PPD-quinone in human and rat liver microsomes: Kinetics, pathways, and mechanism

Zhang, Y., Huang, J., Liu, Y.-H., Zhang, J., Huang, Z. W., Liu, Y., Zhao, J., & Ying, G. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123514 · Cited by 61 · see citing works

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes

Wang, X., Rao, J., Tan, Z., Xun, T., Zhao, J., & Xixiao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043836 · Cited by 60 · see citing works

A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula

Li, M., Wang, Y., Chen, Y., Dong, L., Liu, J., Dong, Y., Yang, Q., Cai, W., Li, Q., Peng, B., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108728 · Cited by 58 · see citing works

The Role of the Kynurenine/AhR Pathway in Diseases Related to Metabolism and Cancer

Shadboorestan, A., Koual, M., Dairou, J., & Coumoul, X. (2023) · International Journal of Tryptophan Research · doi:10.1177/11786469231185102 · Cited by 54 · see citing works

Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database

Morris, R., Ali, R., & Cheng, F. (2024) · Current Drug Targets · doi:10.2174/0113894501290296240327081624 · Cited by 53 · see citing works

Cas12a-based one-pot SNP detection with high accuracy

Zhang, H., Zhang, C., Lu, S., Tong, X., Zhang, K., Yin, H., & Zhang, Y. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100080 · Cited by 52 · see citing works

Electrochemical transformations catalyzed by cytochrome P450s and peroxidases

Kumar, N., He, J., & Rusling, J. F. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00461a · Cited by 50 · see citing works

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy

Ruglioni, M., Crucitta, S., Luculli, G. I., Tancredi, G., Giudice, M. L. D., Mechelli, S., Galimberti, S., Danesi, R., & Re, M. D. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104424 · Cited by 50 · see citing works

Flavonoids as CYP3A4 Inhibitors In Vitro

Kondža, M., Brizić, I., & Jokić, S. (2024) · Biomedicines · doi:10.3390/biomedicines12030644 · Cited by 48 · see citing works

Digital alchemy: Exploring the pharmacokinetic and toxicity profiles of selected coumarin-heterocycle hybrids

Zeki, N. M., & Mustafa, Y. F. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101754 · Cited by 46 · see citing works

Pulling back the mitochondria’s iron curtain

David, S. B. Z., Shkuri, L., & Ast, T. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00045-y · Cited by 46 · see citing works

Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches

Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44 · see citing works

Pharmacokinetic and pharmacodynamic herb-drug interactions—part I. Herbal medicines of the central nervous system

Czigle, S., Nagy, M., Mladěnka, P., Tóth, J., & OEMONOM., T. (2023) · PeerJ · doi:10.7717/peerj.16149 · Cited by 43 · see citing works

Machine learning small molecule properties in drug discovery

Schapin, N., Majewski, M., Varela‐Rial, A., Arróniz, C., & Fabritiis, G. D. (2023) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2023.100020 · Cited by 44 · see citing works

Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors

Zeng, S., Qing, Q., Xu, W., Yu, S., Zheng, M., Tan, H., Peng, J., & Huang, J. Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365524 · Cited by 49 · see citing works

The pharmacology of vitamin C

Lykkesfeldt, J., Carr, A. C., & Tveden‐Nyborg, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100043 · Cited by 44 · see citing works

Driving forces and large scale affinity calculations for piperine/γ-cyclodxetrin complexes: Mechanistic insights from umbrella sampling simulation and DFT calculations

Kumar, P., & Purohit, R. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122350 · Cited by 40 · see citing works

Androgen receptor pathway inhibitors and drug–drug interactions in prostate cancer

Bölek, H., Yazgan, S. C., Yekedüz, E., Kaymakcalan, M. D., McKay, R. R., Gillessen, S., & Ürün, Y. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103736 · Cited by 44 · see citing works

Pharmacogenetic Approaches in Personalized Medicine for Postoperative Pain Management

do Couto, M. L. F., Fonseca, S., & Pozza, D. H. (2024) · Biomedicines · doi:10.3390/biomedicines12040729 · Cited by 39 · see citing works

Computational Bioprospecting Guggulsterone against ADP Ribose Phosphatase of SARS-CoV-2

Kciuk, M., Mujwar, S., Rani, I., Munjal, K., Gielecińska, A., Kontek, R., & Shah, K. (2022) · Molecules · doi:10.3390/molecules27238287 · Cited by 39 · see citing works

The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?

Bosch, E., Sommer, I. E., & Touw, D. J. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2481891 · Cited by 38 · see citing works

Novel ACE-inhibiting peptides from soybean protein hydrolysates by peptidomics combined with in silico analysis and their inhibitory effects on proliferation and migration of Ang II-induced VSMCs

Zhang, T., Cai, Q., Gu, Z., & Song, T. (2024) · Food & medicine homology. · doi:10.26599/fmh.2024.9420023 · Cited by 39 · see citing works

Research progress on pharmacokinetics, anti-inflammatory and immunomodulatory effects of kaempferol.

Li, S.-R., Wang, S.-W., Zhang, L., Ka, Y., Zhou, M.-J., Wang, Y.-W., Tang, Z., Zhang, J., Wang, W., & Liu, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114387 · Cited by 38 · see citing works

A review on pharmacokinetics of sinomenine and its anti-inflammatory and immunomodulatory effects

Wang, S., Zhang, L., Zhou, Y., Liu, Z., Zhou, Z., & Huang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110227 · Cited by 35 · see citing works

The direct targets of metformin in diabetes and beyond

Yao, L., Wang, L., Zhang, R., Soukas, A. A., & Wu, L. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.017 · Cited by 39 · see citing works

Unlocking nature’s secrets: a review on the pharmacokinetics of plant-based medicines and herbal remedies

Parthasarathy, S., Aly, S. H., Tharumasivam, S. V., Bupesh, G., Janani, C., Purushothaman, T., Hafeez, M. S. A. E., & El-Shazly, M. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2513583 · Cited by 35 · see citing works

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers

Abouir, K., Exquis, N., Gloor, Y. S., Daali, Y., & Samer, C. F. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3378 · Cited by 34 · see citing works

Parallel Implementation of the Density Matrix Renormalization Group Method Achieving a Quarter petaFLOPS Performance on a Single DGX-H100 GPU Node

Menczer, A., Damme, M. V., Rask, A. E., Huntington, L. M. J., Hammond, J. R., Xantheas, S. S., Ganahl, M., & Legeza, Ö. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c00903 · Cited by 34 · see citing works

Heavy Metals, Halogenated Hydrocarbons, Phthalates, Glyphosate, Cordycepin, Alcohol, Drugs, and Herbs, Assessed for Liver Injury and Mechanistic Steps

Teschke, R., & Xuan, T. D. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2711314 · Cited by 35 · see citing works

Alzheimer’s Precision Neurology: Epigenetics of Cytochrome P450 Genes in Circulating Cell-Free DNA for Disease Prediction and Mechanism

Bahado-Singh, R. O., Vishweswaraiah, S., Türkoğlu, O., Graham, S. F., & Radhakrishna, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032876 · Cited by 33 · see citing works

Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms

Stelmach, A., Guzek, K., Rożnowska, A., Najbar, I., & Sadakierska−Chudy, A. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00440-6 · Cited by 32 · see citing works

Boswellic acids as promising agents for the management of brain diseases

Rajabian, A., Farzanehfar, M., Hosseini, H., Arab, F. L., & Nikkhah, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121196 · Cited by 32 · see citing works

Unveiling the therapeutic promise of natural products in alleviating drug‐induced liver injury: Present advancements and future prospects

Singh, D., Khan, M. A., & Siddique, H. R. (2023) · Phytotherapy Research · doi:10.1002/ptr.8022 · Cited by 31 · see citing works

Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Latham, B. D., Geffert, R. M., & Jackson, K. D. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001430 · Cited by 31 · see citing works

Harnessing machine learning to predict cytochrome P450 inhibition through molecular properties

Zahid, H., Tayara, H., & Chong, K. T. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03756-9 · Cited by 31 · see citing works

Pharmacogenomic Clinical Support Tools for the Treatment of Depression

Baum, M. L., Widge, A. S., Carpenter, L. L., McDonald, W. M., Cohen, B. M., & Nemeroff, C. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230657 · Cited by 31 · see citing works

A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction

Sun, B., Liang, Z., Wang, Y., Yu, Y., Zhou, X., Geng, X., & Li, B. (2024) · Toxicology · doi:10.1016/j.tox.2024.153829 · Cited by 30 · see citing works

Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA)

Khaleel, E. F., Sabt, A., Korycka‐Machała, M., Badi, R. M., Son, N. T., Ha, N. X., Hamissa, M. F., Elsawi, A. E., Elkaeed, E. B., Dziadek, B. R., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107138 · Cited by 29 · see citing works

Investigation of in silico studies for cytochrome P450 isoforms specificity

Wei, Y., Palazzolo, L., Mariem, O. B., Bianchi, D., Laurenzi, T., Guerrini, U., & Eberini, I. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.08.002 · Cited by 29 · see citing works

Effects of Berberis vulgaris, and its active constituent berberine on cytochrome P450: a review

Bathaei, P., Imenshahidi, M., & Hosseinzadeh, H. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03326-x · Cited by 29 · see citing works

In silico molecular docking and ADMET prediction of biogenic zinc oxide nanoparticles: characterization, and in vitro antimicrobial and photocatalytic activity

Akhter, H., Ritu, S. S., Siddique, S., Chowdhury, F., Chowdhury, R. T., Akhter, S., & Hakim, M. (2024) · RSC Advances · doi:10.1039/d4ra06890d · Cited by 29 · see citing works

ADMET and Physicochemical Assessments in Drug Design

Çevik, U. A., Işık, A., & Karakaya, A. (2024) · doi:10.1002/9781394249190.ch6 · Cited by 29 · see citing works

Local Electric Fields Drives the Proton-Coupled Electron Transfer within Cytochrome P450 Reductase

Li, N., Yan, S., Wu, P., Li, J., & Wang, B. (2024) · ACS Catalysis · doi:10.1021/acscatal.4c02215 · Cited by 28 · see citing works

Cytochrome P450 monooxygenase systems: Diversity and plasticity for adaptive stress response

Mokhosoev, I. M., Astakhov, D. V., Terentiev, A. A., & Moldogazieva, N. T. (2024) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2024.09.003 · Cited by 29 · see citing works

Human toxicity of polybrominated diphenyl ethers (PBDEs) and their derivatives: A comprehensive review

Gao, J., Xie, Z., Wang, Z., Yu, Y., Qi, Z., Yu, X., Zhong, T., Wang, L., Feng, K., Peng, Y., et al. (2024) · Current Research in Food Science · doi:10.1016/j.crfs.2024.100918 · Cited by 28 · see citing works

Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation

Durairaj, P., & Liu, Z. L. (2025) · Journal of Xenobiotics · doi:10.3390/jox15020044 · Cited by 28 · see citing works

Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles

Chamboko, C. R., Veldman, W., Tata, R. B., Schoeberl, B., & Bishop, Ö. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043383 · Cited by 28 · see citing works

Unveiling the antitumor potential of novel N-(substituted-phenyl)-8-methoxycoumarin-3-carboxamides as dual inhibitors of VEGFR2 kinase and cytochrome P450 for targeted treatment of hepatocellular carcinoma

Radwan, E. M., Abo-Elabass, E., El-Baky, A. E. A., Alshwyeh, H. A., Almaimani, R. A., Almaimani, G., Ibrahim, I. A. A., Albogami, A., Jaremko, M., Alshawwa, S. Z., et al. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1231030 · Cited by 28 · see citing works

Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity

Karamperis, K., Katz, S., Melograna, F., Ganau, F. P., Steen, K. V., Patrinos, G. P., & Lao, Ó. (2024) · iScience · doi:10.1016/j.isci.2024.110916 · Cited by 28 · see citing works

Drug-likeness analysis, in silico ADMET profiling of compounds in Kedrostis foetidissima (Jacq.) Cogn, and antibacterial activity of the plant extract

Kommidi, S., Alivelu, M., & Mohammad, M. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00240-1 · Cited by 26 · see citing works

Therapeutic, and pharmacological prospects of nutmeg seed: A comprehensive review for novel drug potential insights

Al-Rawi, S. S., Ibrahim, A. H., Ahmed, H. J., & Khudhur, Z. O. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102067 · Cited by 25 · see citing works

Bioinformatics analysis to disclose shared molecular mechanisms between type-2 diabetes and clear-cell renal-cell carcinoma, and therapeutic indications

Ahmmed, R., Hossen, M. B., Ajadee, A., Mahmud, S., Ali, M. A., Mollah, M. M. H., Reza, M. S., Islam, M. A., & Mollah, M. N. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-69302-w · Cited by 25 · see citing works

Bridging organ transcriptomics for advancing multiple organ toxicity assessment with a generative AI approach

Li, T., Chen, X., & Tong, W. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01317-z · Cited by 25 · see citing works

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

Peña-Flores, J. A., Bermúdez, M., Ramos‐Payán, R., Villegas‐Mercado, C. E., Soto‐Barreras, U., Muela‐Campos, D., Álvarez-Ramírez, A., Perez‐Aguirre, B., Larrinúa-Pacheco, A. D., López‐Camarillo, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.965628 · Cited by 25 · see citing works

Cytochromes P450 involved in bacterial RiPP biosyntheses

Kunakom, S., Otani, H., Udwary, D., Doering, D. T., & Mouncey, N. J. (2023) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuad005 · Cited by 25 · see citing works

CYP1A inhibitors: Recent progress, current challenges, and future perspectives

Dai, Z., Wu, Y., Xiong, Y., Wu, J., Wang, M., Sun, X., Ding, X., Yang, L., Sun, X., & Ge, G. (2023) · Medicinal Research Reviews · doi:10.1002/med.21982 · Cited by 26 · see citing works

Recent Update on Pharmacokinetics and Drug Metabolism in CNS-based Drug Discovery

Sanap, S. N., Bisen, A. C., Kedar, A. S., Agrawal, S., & Bhatta, R. S. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230707121415 · Cited by 26 · see citing works

Drug metabolism

Stanley, L. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18657-8.00029-3 · Cited by 25 · see citing works

Microfluidic systems for modeling digestive cancer: a review of recent progress

Razavi, Z., Soltani, M., Pazoki-Toroudi, H., & Dabagh, M. (2024) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ad6f15 · Cited by 24 · see citing works

Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

Klopp‐Schulze, L., Gopalakrishnan, S., Yalkinoglu, Ö., Kuroki, Y., Lu, H., Goteti, K., Krebs‐Brown, A., Filho, M. A. F. N., Gradhand, U., Fluck, M., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3216 · Cited by 24 · see citing works

Synthesis, antidiabetic activity and in silico studies of benzo[b]thiophene based small molecule α-amylase inhibitors

Joshi, R. J., Dholariya, M. P., Chothani, S. R., Chamakiya, C. A., Varu, H. L., Karmur, M. B., Maliwal, D., Pissurlenkar, R. R. S., Bapodra, A. H., Patel, A. S., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138570 · Cited by 24 · see citing works

Aldo-keto reductases: Role in cancer development and theranostics

Nagini, S., Kallamadi, P. R., Tanagala, K. K. K., & Reddy, G. B. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.049918 · Cited by 25 · see citing works

Hazardous Interactions Between Food, Herbs, and Drugs in the First Stage of Biotransformation: Case Reports of Adverse Drug Interactions in Humans

Bukowska, B., Grzegorowska, A., Szczerkowska‐Majchrzak, E., Bukowski, K., Kadac-Czapska, K., Grembecka, M., & Broncel, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115188 · Cited by 24 · see citing works

Hispidulin: a promising anticancer agent and mechanistic breakthrough for targeted cancer therapy

Chaudhry, G.-E.-S., Zeenia, Sharifi‐Rad, J., & Călina, D. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02645-9 · Cited by 24 · see citing works

Drug-induced interstitial lung disease: a narrative review of a clinical conundrum

Harrison, M. L., Kavanagh, G., Corte, T. J., & Troy, L. K. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2329612 · Cited by 23 · see citing works

The role of the cytochrome P450 superfamily in the skin

Chen, Q., Wang, T., Wu, X., Yuan, H., Wei, Y., & Xiao, Y. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.5 · Cited by 23 · see citing works

Biomimetic culture substrates for modelling homeostatic intestinal epithelium in vitro

Abdollahi, S., Zarin, B., Vatani, M., Vajhadin, F., Hassani, M., Jalali, P., Kim, K., & Sanati‐Nezhad, A. (2025) · Nature Communications · doi:10.1038/s41467-025-59459-x · Cited by 23 · see citing works

Pharmacokinetic Boosting of Kinase Inhibitors

Westra, N., Touw, D. J., Hooge, M. N. L., Kosterink, J. G. W., & Munnink, T. H. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041149 · Cited by 23 · see citing works

FMO family may serve as novel marker and potential therapeutic target for the peritoneal metastasis in gastric cancer

Gong, X., Hou, D., Zhou, S., Tan, J., Zhong, G., Yang, B., Xie, L., Han, F., & Zhong, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144775 · Cited by 23 · see citing works

Insights into Inhalation Drug Disposition: The Roles of Pulmonary Drug-Metabolizing Enzymes and Transporters

Dong, L., & Zhuang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094671 · Cited by 23 · see citing works

Direct oral anticoagulants in cirrhosis: Rationale and current evidence

Portela, C. P., Gautier, L. A., Zermatten, M. G., Fraga, M. C., Moradpour, D., Calderara, D. B., Aliotta, A., Veuthey, L., Gottardi, A. D., Stirnimann, G., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101116 · Cited by 23 · see citing works

Dynamic panoramic presentation of skin function after fractional CO2 laser treatment

Guo, H., Zhang, X., Li, H., Fu, C., Jiang, L., Hu, Y., Huang, J., Chen, J., & Zeng, Q. (2023) · iScience · doi:10.1016/j.isci.2023.107559 · Cited by 22 · see citing works

A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease

Jiang, Y., Cao, Y.-M., Cao, Y., Yan, T., Jia, C., & He, P. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s449494 · Cited by 22 · see citing works

Magnetic catalyst marvels: a sustainable approach to highly substituted imidazole synthesis

Kazemi, M., Javahershenas, R., Makasana, J., Ballal, S., Kadheem, M., Singh, A., Chennakesavulu, K., & Joshi, K. K. (2025) · Nanoscale Advances · doi:10.1039/d5na00368g · Cited by 22 · see citing works

Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice

Goodarzi, G., Tehrani, S. S., Panahi, G., Bahramzadeh, A., & Meshkani, R. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109369 · Cited by 22 · see citing works

Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain

Burris‐Hiday, S. D., & Scott, E. E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105112 · Cited by 22 · see citing works

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

Lennep, B., Mack, J., Poondru, S., Hood, E., Looney, B. D., Williams, M., Bianco, J. J., & Morgans, A. K. (2024) · Drug Safety · doi:10.1007/s40264-024-01415-7 · Cited by 22 · see citing works

The botanical details, pharmacological activities and industrial applications of date seed (Phoenix dactylifera L.)

Nwachukwu, S. C., Edo, G. I., Samuel, P. O., Jikah, A. N., Oloni, G. O., Ezekiel, G. O., & Agbo, J. J. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-09967-3 · Cited by 22 · see citing works

Metabolic Stability of Fluorinated Small Molecules: A Physical Organic Chemistry Perspective

Bhattarai, P., Trombley, T. A., & Altman, R. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02359 · Cited by 21 · see citing works

CYP35 family in Caenorhabditis elegans biological processes: fatty acid synthesis, xenobiotic metabolism, and stress responses

Lim, S. Y. M., Alshagga, M. A., Kong, C., Alshawsh, M. A., Alshehade, S. A., & Pan, Y. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03382-3 · Cited by 21 · see citing works

Advanced Strategies of Drug Delivery via Oral, Topical, and Parenteral Administration Routes: Where Do Equine Medications Stand?

Song, Y., Day, C. M., Afinjuomo, F., Tan, J. Q. E., Page, S. W., & Garg, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010186 · Cited by 21 · see citing works

Evolutionary conservation analysis of human arachidonic acid metabolism pathway genes

Wei, C., Wang, M., & Wang, X. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad004 · Cited by 21 · see citing works

The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice

Zhu, Y., Chen, L., He, Y., Qin, L., Tan, D., Bai, Z., Song, Y., & Wang, Y.-H. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2202359 · Cited by 21 · see citing works

Cytochrome P450 Polymorphisms

Zanger, U. M. (2012) · Encyclopedia of Drug Metabolism and Interactions · doi:10.1002/9780470921920.edm009 · Cited by 2 · see citing works

Cytochrome P450

Bhatia, K. S., Mahesh, A. N., & Bhatt, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00696-5 · Cited by 2 · see citing works

Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

Zhou, S.-F., & Sneed, K. (2014) · doi:10.1201/b15465-16 · Cited by 1 · see citing works

Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance

Al‐Omari, A., & Murry, D. J. (2007) · Journal of Pharmacy Practice · doi:10.1177/0897190007304821 · Cited by 43 · see citing works

Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes

Song, Y., Li, C., Liu, G., Liu, R., Chen, Y., Li, W., Cao, Z., Zhao, B., Lu, C. C., & Liu, Y. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01001-5 · Cited by 114 · see citing works